Summary
Advanced glycation end-product-formation is thought to play a role in the development of diabetic angiopathy. By altering the structure of different extracellular matrix components advanced glycation end-products might affect vascular and glomerular permeability. In this study we investigated the effect of treatment with an inhibitor of advanced glycation end-product-formation, aminoguanidine, on vascular permeability and the development of albuminuria in streptozotocin-induced diabetic rats. Male Wistar Rp rats were randomized into a control group, a diabetic group, and an aminoguanidine-treated diabetic group. After 8 weeks, 24-h urine collections were taken and rats were implanted with an arterial and a venous catheter. Mean arterial blood pressure was determined by intra-arterial measurement. Regional albumin clearances were assessed in the eye, ileum, lung, skeletal muscle and skin using an isotope technique. Mean arterial pressure in the diabetic group was significantly lower in the control and aminoguanidine-treated groups (p<0.02). Regional albumin clearances were significantly increased in all tissues of diabetic rats compared to control rats (p<0.05). Aminoguanidine treatment of diabetic rats resulted in a significant decrease of regional albumin clearance in all tissues except the lung (p<0.05, lung p=0.07). The development of albuminuria in diabetic rats however, was not affected by aminoguanidine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Brownlee M (1992) Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15: 1835–1843
Tsilbary EC, Charonis AS, Reger LA, Wohlhueter RM, Furcht LT (1988) The effect of non-enzymatic glycosylation on the binding of the main non-collagenous NCl domain to type IV collagen. J Biol Chem 263: 4302–4308
Charonis AS, Reger LA, Dege JE et al. (1990) Laminin alterations after in vitro non-enzymatic glycosylation. Diabetes 39: 807–814
Shimomura H, Spiro RG (1987) Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36: 374–381
Wu V-Y, Wilson B, Cohen MP (1987) Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes. Diabetes 36: 679–683
Feldt-Rasmussen B (1986) Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia: 29: 282–286
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32: 219–226
Williamson JR, Chang K, Tilton RG et al. (1987) Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozotocin-induced diabetes. Prevention by aldose reductase inhibitors and castration. Diabetes 36: 813–821
Tucker BJ, Blantz RC, Rasch R (1992) Glomerular filtration and tubular reabsorption of albumin in early and established STZ-diabetic rats. Diabetologia 35: A11 (Abstract)
Thomas G, Ramwell PW (1991) Effects of guanodino compounds on the endothelium-derived relaxing factor inhibitor NG-monomethyl L-arginine. J Pharmacol Exp Ther 259: 490–494
Edelstein D, Brownlee M (1992) Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35: 96–97
Corbett JA, Tilton RG, Chang K et al. (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552–556
Huijberts MSP, Wolffenbuttel BHR, Crijns FRL et al. (1993) Angiotensin converting enzyme-inhibition reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes. Eur J Pharmacol 240: 207–212
Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87: 432–438
Tilton RG, Chang KG, Pugliese G et al. (1989) Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 38: 1258–1270
Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunological detection of advanced glycosylation endproducts in vivo. J Biol Chem 267: 5133–5138
Kusaka M, Kishi K, Sokabe H (1987) Does so-called streptozotocin hypertension exists in rats? Hypertension 10: 517–521
Tomlinson KC, Gardiner SM, Bennett T (1990) Blood pressure in streptozotocin-treated Brattleboro and Long Evans rats. Am J Physiol 258: R852-R859
Laurell C-B (1972) Electroimmunoassay. Scand J Lab Clin Invest 29 [Suppl 124]: 21
Pugliese G, Tilton RG, Speedy A et al. (1990) Modulation of hemodynamic and vascular filtration changes in diabetic rats by dietary myo-inositol. Diabetes 39: 312–322
Williamson JR, Holmberg SW, Chang KG, Marvel J, Sutera S, Needleman P (1989) Mechanisms underlying atriopeptin-induced increases in hematocrit and vascular permeation in rats. Circ Res 64: 890–899
de Vries PJF, Tyssen C, Struijker Boudier HAJ, Smits JFM (1990) Atrial natriuretic factor increases albumin extravasation in conscious rats. Eur J Physiol 415: 507–509
Bent-Hansen L (1991) Whole body capillary exchange of albumin. Acta Physiol Scand 143: 5–10
Bent-Hansen L (1991) Initial plasma disappearance and tissue uptake of 131I-albumin in normal rabbits. Microvasc Res 41: 345–356
Tucker BJ (1990) Early onset of increased transcapillary escape rate in awake diabetic rats. Diabetes 39: 919–923
Tilton RG, Chang K, Hasan KS et al. (1993) Prevention of vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42: 221–232
Hill MA, Larkins RG (1989) Alterations in the distribution of cardiac output in experimental diabetes in rats. Am J Physiol 257: H571-H580
Huijberts MSP, Wolffenbuttel BHR, Struijker Boudier HAJ et al. (1993) Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92: 1407–1411
Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA (1991) Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci US A 88: 6107–6111
Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums J (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40: 1328–1334
Anderson S, Rennke HG, Garcia DL, Brenner BM (1989) Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36: 526
Parving H-H, Andersen AR, Schmidt UM, Hommel E, Mathiesen ER, Svendsen PA (1987) Effect of anti-hypertensive treatment on kidney function in diabetic nephropathy. BMJ 294: 1443–1445
Borch-Johnsen K, Kreiner S (1987) Proteinuria — A predictor of cardiovascular mortality in insulin-dependent diabetes mellitus. BMJ 294: 1651–1654
Deckert TD, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T (1992) Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care 15: 1181–1191
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huijberts, M.S.P., Wolffenbuttel, B.H.R., Crijns, F.R.L. et al. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 37, 10–14 (1994). https://doi.org/10.1007/BF00428771
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00428771